Damora Therapeutics Cash Flow Statement
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
21.08+0.52 (+2.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Damora Therapeutics free cash flow
In fiscal 2025, Damora Therapeutics generated -$6.7 million of operating cash flow. That left free cash flow of -$6.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Damora Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 22.00K | 21.00K | 269.00K | 42.00K | 20.00K | — | — |
| Stock-Based Compensation | 998.00K | 3.24M | 5.43M | 5.57M | 4.48M | 982.00K | — |
| Change in Working Capital | -87.00K | -371.00K | -1.58M | 8.05M | -5.52M | -1.07M | 718.00K |
| Operating Cash Flow | -6.73M | -18.62M | -36.91M | -42.93M | -52.31M | -38.20M | -19.33M |
| Capital Expenditures | — | — | — | -196.00K | -223.00K | — | — |
| Investing Cash Flow | -17.37M | 11.65M | 22.33M | 12.38M | -48.05M | — | -326.00K |
| Financing Cash Flow | 266.84M | — | 2.88M | 507.00K | — | 187.39M | — |
| Net Change in Cash | 242.74M | -6.97M | -11.71M | -30.04M | -100.36M | 149.19M | -19.65M |
| Free Cash Flow | -6.73M | -18.62M | -36.91M | -43.13M | -52.53M | -38.20M | -19.33M |
This table shows 7 annual periods of Damora Therapeutics's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DMRA's reporting calendar. What is a cash flow statement?